Full Article
Evidence Summary
What is an Evidence Summary?
Key messages from scientific research that's ready to be acted on
Got It, Hide thisIn people with advanced non-small cell lung cancer, combined with other medications, carboplatin and cisplatin do not differ for overall or 1-year survival
de Castria TB, da Silva EMK, Gois AFT, et al.. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013:8:CD009256.
Review question
How effective and safe is carboplatin compared with cisplatin in people with advanced non-small cell lung cancer?
Background
2 major types of lung cancer are small cell lung cancer and non-small cell lung cancer. About 85 to 90% of lung cancers are non-small cell lung cancer.
Newer anticancer medications with different action mechanisms (third-generation drugs) are available. These medications—in combination with cisplatin—are standard chemotherapy for advanced non-small cell lung cancer. However, carboplatin chemotherapy may have a different toxicity profile.
The aim of treatment for people with advanced non-small cell lung cancer is only to provide relief from pain and distress.
How the review was done
This systematic review included 10 randomized controlled trials of 5,017 people aged 18 to 75 years with advanced non-small cell lung cancer. The publication period was 2001 to 2011.
Carboplatin was compared with cisplatin—both in combination with a third-generation drug (gemcitabine, paclitaxel, or docetaxel).
Outcomes were overall survival, 1-year survival rate, quality of life, and toxic effects.
What the researchers found
Overall survival
- Carboplatin and cisplatin—both in combination with a third-generation drug—did not differ in overall survival.
1-year survival
- Carboplatin and cisplatin—both in combination with a third-generation drug—did not differ in 1-year survival.
Drug toxicities
- Cisplatin caused about 2.3 times more nausea or vomiting events, or both, than carboplatin.
- Carboplatin caused about 2 times more low platelet count events (which can cause bleeding) than cisplatin.
- Carboplatin caused about 1.5 times more nerve toxicity events (which cause numbness or pain) than cisplatin.
- Carboplatin and cisplatin did not differ for anemia, skin rash, white blood cell deficiency, hair loss, or kidney toxicity.
Conclusions
In people with advanced non-small cell lung cancer, combined with a third-generation drug, carboplatin and cisplatin do not differ for overall and 1-year survival.
Cisplatin causes more nausea or vomiting. Carboplatin causes more low-platelet count and nerve toxicity events.
Related Topics
Glossary
Studies where people are assigned to one of the treatments purely by chance.
A comprehensive evaluation of the available research evidence on a particular topic.
Related Evidence Summaries
-
Communication skills training for healthcare professionals working with people who have cancer
Cochrane Database of Systematic Reviews (2018)
-
Educational interventions are effective in improving knowledge about cancer risk reduction among men
Patient Education and Counseling (2018)
-
Automated telephone communication systems for preventive healthcare and management of long-term conditions
Cochrane Database of Systematic Reviews (2016)
